Press release
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature cardiovascular diseases. About 1 in 250 people around the world have HeFH and only about 10% of people with this medical condition have been diagnosed. Diagnosis is important because there are several early aggressive treatments available which can lower the risk for heart diseases or stroke.
Get the detailed analysis @ https://www.pharmaproff.com/report/hefh-therapeutics-pipeline-analysis
The drug candidates of HeFH pipeline include, but not limited to, GEM-201 and anacetrapib. Some of the other companies having drugs in the HeFH pipeline includes Gemphire Therapeutics Inc. and Merck & Co. Inc.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1135
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis here
News-ID: 1727305 • Views: …
More Releases for HeFH
Heterozygous Familial Hypercholesterolemia (HeFH) Market to Reach USD 33.41 Bill …
Pune, India - December 2025 - The global Heterozygous Familial Hypercholesterolemia (HeFH) Market, valued at USD 18.27 billion in 2024, is projected to reach USD 33.41 billion by 2034, growing at a 6.1% CAGR (2025-2034), according to Exactitude Consultancy. Increasing global adoption of PCSK9 inhibitors, improved genetic screening, and rising focus on early cardiovascular disease prevention are driving strong market expansion.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72023
Market…
Europe and U.S. Heterozygous Familial Hypercholesterolemia (HEFH) Management Mar …
The Europe and U.S. Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Outlook 2025-2035 highlights an era of accelerating innovation and long-term growth across diagnostics and advanced lipid-lowering therapies. Early identification programs, genomic technologies, and evolving cardiovascular care frameworks are supporting remarkable expansion. The global market continues to scale as key regions strengthen clinical awareness and integrate next-generation interventions. As documented in the latest analysis, the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market…
Heterozygous Familial Hypercholesterolemia (HeFH) Market to Reach USD 12 Billion …
Heterozygous Familial Hypercholesterolemia (HeFH) is a common yet underdiagnosed genetic disorder that significantly elevates low-density lipoprotein cholesterol (LDL-C) levels from birth. Affecting approximately 1 in 250 individuals worldwide, HeFH increases the risk of premature cardiovascular disease and heart attacks. Caused by mutations in genes such as LDLR, APOB, and PCSK9, HeFH requires lifelong management, typically with lipid-lowering therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72023
In recent years, the…
Heterozygous Familial Hypercholesterolemia Drug Market Comprehensive Industry Tr …
The Heterozygous Familial Hypercholesterolemia (HeFH) Drug market is experiencing significant growth, driven by increasing awareness of cardiovascular diseases and the urgent need for effective cholesterol-lowering therapies. HeFH is a genetic condition that leads to elevated levels of low-density lipoprotein (LDL) cholesterol, raising the risk of heart disease. As healthcare systems aim to combat the rising prevalence of cardiovascular disorders, the demand for innovative treatments for HeFH is at an all-time…
Future of Heterozygous Familial Hypercholesterolemia Drug Market: Analysis and L …
𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐚𝐧𝐝 𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬
The Heterozygous Familial Hypercholesterolemia (HeFH) Drug Market is experiencing significant growth, characterized by the increasing prevalence of high cholesterol levels and the corresponding need for effective treatment solutions. HeFH is a genetic disorder that leads to elevated levels of low-density lipoprotein (LDL) cholesterol in the bloodstream, resulting in a heightened risk of cardiovascular diseases. This market is not only relevant for healthcare providers but…
Insights on the Heterozygous Familial Hypercholesterolemia Drug Market to 2027 | …
The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial…
